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Wereadwith great interest the recent article “Diagnosis andManagement of Osteonecrosis of the Jaw: A Systematic
Review and International Consensus” by Khan and colleagues.(1)
Medication-related osteonecrosis of the jaw (MRONJ) is a
potentially severe adverse side effect of antiresorptive agents, and
although a signiﬁcant body of literature has been produced, there
remains little evidence-based guidance for clinicians with respect to
most aspects of this disease. Therefore, we applaud the attempt of
Khan and colleagues to provide a much-needed systematic review.
However,it isimportantthatanyreviewonthistopicisaddressed
on thebasis of thebest available evidence and abalancedanalysis
of the literature. More importantly, systematic reviews require
rigorous research methods and a clear and transparent presenta-
tion of results in order to limit bias and maximize readability.(2–4)
In the work of Khan and colleagues,(1) we have identiﬁed several
issues that we suggest carry a risk of affecting the validity of their
results.
Assessing the risk of bias is a crucial part of systematic
reviews.(5,6) Khan and colleagues presented the criteria they
used to assign level of evidence and grade recommendations,
but unfortunately provided little information regarding
qualitative assessment of reviewed studies, related risk of
bias, as well as the process of article selection. Overall, it is hard
to understand how and why articles were selected or excluded.
The presentation of data on incidence and prevalence makes
the interpretation of the results difﬁcult. It is well established
that incidence data without deﬁnition of a time period can be
meaningless;(7) nevertheless, results upon incidence of MRONJ
are in several instances presented without mentioning the
relevant time frame. There are also inconsistencies between
different sections of the article: For example, in the abstract, it is
stated that “in the osteoporosis patient population MRONJ
incidence is estimated at 0.001 to 0.01%,” whereas different
ﬁgures are reported in the results (0.15% to <0.001% person-
years of exposure). Furthermore, the authors state that the
prevalence of MRONJ in the oncological setting ranges from “0
to 0.186%” whereas the work of Walter and colleagues, which
they cite, reports a prevalence of 18.6%.(8)
Khan and colleagues report that the incidence of MRONJ in
the osteoporosis population would only be “marginally higher
than the incidence in the general population,” which in the
abstract is reported to be <0.001%.(1) This statement is quite
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confusing because it remains unclear what they mean by
“incidence of jaw necrosis in the general population.” Possibly
the authors refer to other disorders that may cause jaw necrosis
in the absence of antiresorptive therapy. We wonder whether it
is appropriate to associate different populations with different
disorders when incidence/prevalence is discussed in a system-
atic review. Also, we could not ﬁnd any clear reference in the text
supporting the reported <0.001% incidence; it remains uncer-
tain where this ﬁgure comes from.
We also found it singular and rather unusual for a systematic
review to provide a detailed description of an unrelated, poorly
characterized, and not widely accepted disease entity, namely
oral ulceration and bone sequestration (OUBS).(1) Its relevance to
the intended systematic review on MRONJ remains unclear. The
articles cited in the main part of the paper (Introduction)(9–11) do
not provide convincing evidence regarding the impact this
questionable disease may have upon patients, and certainly
they cannot suggest that a signiﬁcant portion of cases of MRONJ
could, in fact, represent misdiagnosed OUBS.
The deﬁnition of MRONJ continues to cause signiﬁcant
controversy. Khan and colleagues seem to disregard the
suggestions of different independent research groups who
have called for a change in the traditional deﬁnition(12) so as to
include the nonexposed variant of MRONJ,(13–23) which can
represent up to 25% of all cases.(13) We wonder whether the
authors concluded that these articles were in some way ﬂawed
and, therefore, had to be excluded from the systematic review. It
is also rather surprising that they decided not to embrace the
revised 2014 AAOMS consensus, which agrees that individuals
presenting with bone that can be probed via sinus tracts do ﬁt
MRONJ deﬁnition.(24)
With respect to MRONJ treatment, readers would expect a
systematic review toprovide a balanced and fair comparisonof the
outcomes of different interventions, both surgical andnonsurgical.
However, Khan and colleagues suggest that “conservative therapy
is the mainstay of care” with no robust convincing evidence in
support of this statement. Althoughwe agree that there is a lack of
consensus, as well as very little information on the outcomes of
denosumab-related ONJ, we think that this review does not
provide a fair and comprehensive summary of current knowledge
and available evidence.
For example, whenmucosal healing is considered the primary
outcome,(25–28) a number of articles have reported that less than
one-third of patients managed with long-term conservative
treatment, especially in the oncological setting, would show
evidence of mucosal healing (23% and 14.9% of Hoff and
colleagues(29) and Nicolatou-Galitis and colleagues(30) case
series, respectively). This means that the majority of MRONJ
patients managed conservatively would present persistent
jawbone exposure, which not only can affect their quality of
life(31) but may also limit the oncological treatment options,
including further antiresorptive treatment.(32,33) Although
conservative treatment might be adequate to slow down
disease progression and control pain and infections, there is
increasing evidence supporting surgical treatment protocols.
Case series from different research groups report percentages of
mucosal healing that are consistently around and above 80%,
with outcome endpoints ranging from 3months to 7 years post-
treatment. Examples include Carlson and colleagues (92%), (26)
Stockmann and colleagues (89%), (34) Bedogni and colleagues
(90%), (35) Schubert and colleagues (89%), (36) and Jacobsen and
colleagues (78%). (37) Comparative studies also seem to conﬁrm
these results.(38,39) Finally, both the systematic review by Rupel
and colleagues(40) and another recent systematic review
meeting PRISMA guidelines(6) suggest that surgical therapy
can be superior to conservative management.(41)
We feel that these are important aspects completing the
review of Khan and colleagues.(1)
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